Researchers Develop Nasally Delivered DNA Vaccine for Tuberculosis

Key Takeaways

• Intranasal DNA vaccine targets TB persisters
• Fusion of relMtb and Mip3α enhances dendritic recruitment
• Vaccine improves efficacy of bedaquiline‑pretomanid‑linezolid regimen
• Mouse studies show faster bacterial clearance, reduced lung inflammation
• Rhesus macaque immune responses persisted six months, indicating durability

Summary

Johns Hopkins researchers have created an intranasal DNA vaccine that fuses the relMtb and Mip3α genes to target drug‑tolerant tuberculosis persisters. In mouse models the vaccine accelerated bacterial clearance, lowered lung inflammation and prevented relapse when combined with standard therapy. Rhesus macaque studies showed durable, airway‑focused immune responses lasting at least six months. The team suggests the platform could complement existing drug regimens, especially for drug‑resistant TB, pending further pre‑clinical work before human trials.

Pulse Analysis

Tuberculosis remains the world’s deadliest single‑pathogen disease, with the World Health Organization estimating over 10 million new cases and 1.2 million deaths in 2024 alone. The traditional six‑month multidrug regimen is plagued by poor adherence, costly side‑effects, and the rise of multidrug‑resistant strains. Consequently, the WHO has called for therapeutic vaccines that can work alongside antibiotics to shorten treatment duration and improve outcomes. In this context, a DNA‑based approach offers a promising alternative because it is stable, scalable, and can be engineered to express precise antigens that stimulate targeted immunity.

The Johns Hopkins team’s vaccine combines two bacterial genes—relMtb, which encodes a protein that helps Mycobacterium tuberculosis survive hostile conditions, and Mip3α, a chemokine that attracts immature dendritic cells. Delivered through the nose, the formulation concentrates immune activation at the respiratory mucosa, the primary site of infection, while also generating systemic T‑cell responses. Pre‑clinical data in mice demonstrated accelerated clearance of bacilli, reduced pulmonary inflammation, and protection against relapse after standard drug therapy. In rhesus macaques, the same construct elicited robust CD4 and CD8 T‑cell activity in both blood and airways, persisting for at least half a year, suggesting a durable protective effect.

If human trials confirm these findings, the vaccine could become a critical adjunct to existing drug regimens, especially for patients battling drug‑resistant TB where options are limited. By enhancing the host’s immune response, the vaccine may allow clinicians to shorten antibiotic courses, lower toxicity, and reduce the emergence of resistance. Moreover, the DNA platform’s manufacturing simplicity could facilitate rapid scale‑up and distribution in low‑resource settings, addressing the inequities that have long hampered TB control. Investors and public‑health agencies are likely to watch this development closely as a potential game‑changer in the global effort to eradicate tuberculosis.